About the article
Dinna N. Cruz
Dinna N. Cruz, MD, MPH, is Director for Research at the Department of Nephrology, Dialysis and Transplantation at San Bortolo Hospital and the International Renal Research Institute Vicenza (IRRIV) in Vicenza, Italy. As a nephrologist and epidemiologist, her research interests and expertise include extracorporeal blood purification techniques, acute kidney injury and the cardio-renal syndromes. She has authored over several peer-reviewed publications on various aspects of renal and cardiorenal disease in prestigious international journals and has contributed chapters to key international nephrology textbooks. She serves as Associate Editor for Blood Purification and Clinical Kidney Journal and as a reviewer for a number of high ranking Nephrology, ICU, and Internal Medicine journals.
Sérgio Gaião, MD is a nephrologist and is currently working at the General Intensive Care Unit in Hospital São João, Porto, Portugal. During his nephrology training, he did a research fellowship with the International Renal Research Institute of Vicenza (IRRIV). He also lectures in Critical Care Nephrology at the Faculty of Medicine, University of Porto. He is dedicated to clinical research, specifically biomarkers of acute kidney injury and renal replacement therapy, in part in collaboration with IRRIV.
Alan Maisel, MD, is a Professor of Medicine at the University of California, San Diego. He is the Director of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla, California. He is an associate editor of the Journal of the American College Cardiology. Dr. Maisel is considered one of the world’s experts on cardiac biomarkers and has over 150 scientific publications. He has authored several ground-breaking publications that have paved the way for the development of diagnostic tools for patients with congestive heart failure.
Claudio Ronco, MD, is Director of the Department of Nephrology, Dialysis and Transplantation at San Bortolo Hospital and the International Renal Research Institute Vicenza (IRRIV) in Vicenza, Italy. He is Editor-in-Chief of Blood Purification and the former President of the International Society for Hemodialysis (ISHD). He is a member of the council of several scientific societies. He has co-authored 650 papers, 36 book chapters, 45 books and seven monographic journal issues and has delivered more than 450 lectures at international meetings and universities.
Prasad Devarajan, MD, is the Williams Endowed Chair, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of Clinical Laboratories, and CEO of the Dialysis Unit at Cincinnati Children’s Hospital Medical Center and University of Cincinnati. He has authored over 200 peer-reviewed publications. He has been continuously funded by the National Institutes of Health and several other foundations for more than 25 years. His major research interests lie in using proteomic and functional genomic approaches for the discovery of pathogenetic pathways, diagnostic biomarkers, and novel therapies of acute kidney injury and chronic kidney disease. His laboratory has pioneered the discovery, translation, and validation of NGAL as a biomarker of acute kidney injury.
Published Online: 2012-07-07
Published in Print: 2012-09-01